Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, Shota Fujimoto, Junko Watanabe, Hiromichi Hara, Takanori Numata, Kazuyoshi Kuwano, Yoshinori Matsuwaki
BACKGROUND: Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking. METHODS: We retrospectively evaluated the effects of dupilumab in 62 patients who received dupilumab for eosinophilic sinusitis comorbid with asthma at a single centre in Japan. Type 2 inflammatory markers, ACT, respiratory function tests, and forced oscillation technique (FOT) were analysed before, three months after, and one year after dupilumab administration, mainly in patients with mild to moderate asthma...
June 28, 2022: BMC Pulmonary Medicine